The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Highlights in Lymphoma at ASH 2020
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, shares her enthusiasm on recent advances in the lymphoma field presented at ASH 2020. Multiple clinical trials are underway assessing bispecific antibodies in the treatment of large B-cell lymphoma (LBCL) and follicular lymphoma (FL), where high efficacy rates and tolerable safety profiles are being reported. She goes on to discuss the emerging data on CAR T-cell therapy, specifically the ZUMA-5 and ELARA studies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
